K Maedler, J Størling, J Sturis, RA Zuellig … - Diabetes, 2004 - Am Diabetes Assoc Increasing evidence indicates that a progressive decrease in the functional
β-cell mass is the hallmark of both type 1 and type 2 diabetes. The underlying
causes, β-cell apoptosis and impaired secretory function, seem to be ... Cited by 36 - Related articles - All 3 versions
- ►nih.gov A Jahangir, A Terzic - Journal of molecular and cellular cardiology, 2005 - Elsevier The family of potassium channel openers regroups drugs that share the property
of activating adenosine triphosphate-sensitive potassium (K ATP ) channels,
metabolic sensors responsible for adjusting membrane potential-dependent ... Cited by 26 - Related articles - All 12 versions
- ►endojournals.org R Alemzadeh, KM Tushaus - Endocrinology, 2004 - Endocrine Soc Dysregulation of the adipoinsular axis in male obese Zucker diabetic fatty (ZDF;
fa/fa) rats, a model of type 2 diabetes, results in chronic hyperinsulinemia and
increased de novo lipogenesis in islets, leading to ß-cell failure and ... Cited by 14 - Related articles - BL Direct - All 5 versions
K Buschard, M Blomqvist, T Osterbye, P … - Diabetologia, 2005 - Springer Abstract Mammalian tissues express β-isoforms of gly- cosphingolipids and,
among these, sulfatide (sulphated galactosylceramide) is present in the beta
cells, and it is here that the short fatty acid chain (C16) isoform is pre- ... Cited by 10 - Related articles - BL Direct - All 3 versions
A Farret, L Lugo-Garcia, F Galtier, R Gross, P … - Fundam Clin Pharmacol, 2005 - interscience.wiley.com Blood glucose concentration is controlled by a number of hormone and
neurotransmitter signals, either increasing or reducing glucose levels in the
case of hypoglycemia or hyperglycemia, respectively. The pancreatic β-cell ... Cited by 8 - Related articles - BL Direct - All 4 versions
PV Bharatam, DS Patel, L Adane, A Mittal, S … - Current pharmaceutical design, 2007 - ingentaconnect.com Abstract: Diabetes mellitus is a chronic metabolic disorder, characterized by
glucose overproduction and glucose underutilization. Cur- rent therapy for T2DM
includes drugs, like metformin, glitazones, sulphonyl ureas, etc. Extensive ... Cited by 7 - Related articles - BL Direct - All 3 versions
FE Nielsen, P Jacobsen, A Worsaae, POG … - Bioorganic & Medicinal Chemistry Letters, 2004 - Elsevier Only a few different structural types of activators of Kir6.2/SUR1 potassium
channels have been described. These include the 1,2,4-thiadiazine 1,1-dioxide
derivatives like diazoxide, BPDZ 62, BPDZ 73 and NN414 [1] , [2] , [3] and ... Cited by 7 - Related articles - All 3 versions
SC Schou, HC Hansen, TM Tagmose, HCM … - Bioorganic & medicinal chemistry, 2005 - Elsevier 1,2,4-Thiadiazine derivatives, like 3-methyl-7-chlorobenzo-4H-1,2,4-thiadiazine
1,1-dioxide, diazoxide and 7-chloro-3-isopropylamino-4H-benzo-1,2,4-thiadiazine
1,1-dioxide, BPDZ 73, are potent openers of Kir6.2/SUR1 K ATP channels. To ... Cited by 6 - Related articles - All 4 versions
M Blomqvist, M Carrier, T Andrews, K … - Diabetes/Metabolism Reviews - interscience.wiley.com Sulfatide is present in the secretory granules of beta cells and has been shown,
in vitro, to be involved in insulin processing and secretion. Of particular
interest is one of the major sulfatide isoforms in the beta cells, the ... Cited by 6 - Related articles - All 2 versions
